COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration
Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.
With over 50 COVID-19 antibody tests authorized for use under FDA EUA, a milestone has been recognized with the FDA’s Nov. 6, 2020, announcement.
Key update and recommendations released Oct. 26, 2020, that affect SARS-CoV-2 antigen test use.
October 2020 Medicare loan repayment update for providers.
New FDA update to comparative COVID-19 test performance data now includes information about most available SARS-CoV-2 diagnostic molecular tests.
Interim final rule (CMS-3401-IFC) from CMS mandates daily reporting for broader surveillance of COVID-19 and influenza statistics, and outlines strict enforcement mechanisms.
Rollout and availability of rapid SARS-CoV-2 antigen tests opens wave of CLIA certification issues triggering CMS cease and desist letters.
With over 50 COVID-19 antibody tests authorized for use under FDA EUA, a milestone has been recognized with the FDA’s Nov. 6, 2020, announcement.
Key update and recommendations released Oct. 26, 2020, that affect SARS-CoV-2 antigen test use.
October 2020 Medicare loan repayment update for providers.
New FDA update to comparative COVID-19 test performance data now includes information about most available SARS-CoV-2 diagnostic molecular tests.
Interim final rule (CMS-3401-IFC) from CMS mandates daily reporting for broader surveillance of COVID-19 and influenza statistics, and outlines strict enforcement mechanisms.
Rollout and availability of rapid SARS-CoV-2 antigen tests opens wave of CLIA certification issues triggering CMS cease and desist letters.
